U
TXMD icon

UBS’s TherapeuticsMD TXMD Stock Holding History

UBS’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1.17M Buy
5,026
+4,800
+2,124% +$1.21M ﹤0.01% 3441
2014
Q2 		$50K Buy
+226
New +$50.3K ﹤0.01% 6866

Other funds holding TXMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS's TXMD Position: Q3 2014 in Review

UBS reduced its TherapeuticsMD (TXMD) stake by 58% in Q3 2014, selling an estimated $7.05K and leaving 20 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #9493.

UBS first reported a position in TXMD in Q2 2013 and has held it in 5 quarters since. The position peaked at $37K in Q2 2013. 82 funds tracked by Wall St. Rank hold TXMD as of Q3 2014.

  • UBS held 20 shares of TherapeuticsMD worth $5K as of Q3 2014.
  • UBS sold 28 TherapeuticsMD shares in Q3 2014, an estimated $7.05K.
  • TherapeuticsMD made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9493 holding.
  • UBS first reported a position in TherapeuticsMD in Q2 2013 and has held it in 5 quarters since.
  • UBS's TherapeuticsMD position peaked at $37K in Q2 2013.
  • 82 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.